|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.445 USD | +0.20% |
|
+5.17% | +35.56% |
| 05-13 | Protalix BioTherapeutics, Inc., Q1 2026 Earnings Call, May 13, 2026 | |
| 05-13 | Protalix BioTherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | - | 11 | +350.82% | 2 | |||||
| 1,243.43 | +4.61% | 28 | ||||||
| 259 | +0.79% | 22 | ||||||
| 262.93 | +5.99% | 28 | ||||||
| 359.22 | +6.72% | 18 | ||||||
| 153.66 | -0.25% | 21 | ||||||
| 215.33 | +25.02% | 22 | ||||||
| 316.91 | -1.66% | 24 | ||||||
| 355.76 | -2.1% | 29 | ||||||
| 158.3 | +21.93% | 27 | ||||||
| 28.94 | +19.74% | 26 | ||||||
| 554.56 | +14.25% | 25 | ||||||
| 62.96 | +9.34% | 24 | ||||||
| 21.2 | +8.08% | 19 | ||||||
| 96.31 | +26.35% | 23 | ||||||
| 10,006.67 | +35.43% | 15 | ||||||
| 54.28 | +8.3% | 16 | ||||||
| 80.92 | +45.15% | 15 | ||||||
| 6,106.87 | +13.96% | 15 | ||||||
| 4.142 | +14.49% | 17 | ||||||
| Average | 1,017.62 | +30.35% | 21 | ||||||
| Weighted average by Cap. | 709.22 | +8.06% | 24 |
- Stock Market
- Stocks
- PLX Stock
- Sector Protalix BioTherapeutics, Inc.
- Sector consensus
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
